Idorsia Ltd. · SIX:IDIA

Idorsia — Investor Presentation (February 2018)

73 slides from Idorsia's investor presentation, February 2018

  1. Slide 1: Idorsia – Reaching out for more

    Slide 1: Idorsia – Reaching out for more

    Idorsia – Reaching out for more

  2. Slide 2: Forward-looking statements

    Slide 2: Forward-looking statements

    The following information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”,

  3. Slide 3: June 2017 Idorsia

    Slide 3: June 2017 Idorsia

    15 June 2017 3 Idorsia - Reaching out for more | February 2018

  4. Slide 4: The purpose of Idorsia

    Slide 4: The purpose of Idorsia

    The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more patients. 4 Idorsia - Reaching out for more | February 2018

  5. Slide 5: Highlights in 2017

    Slide 5: Highlights in 2017

    Highlights in 2017 Pipeline Results Substantial progress with the pipeline – productive discussions with health authorities Idorsia is born Idorsia created and listed – pipeline advanced without missing a beat Partnerships Development partnership with Janssen Biotech to advance aprocitentan Research

  6. Slide 6: Idorsia Today

    Slide 6: Idorsia Today

    Idorsia Today >650 Highly qualified 11 professionals Compounds in the pipeline, with four progressing to late-stage development in the year ahead >1 bn Swiss francs in cash > 550 State-of-the-art laboratory workspaces 6 Idorsia - Reaching out for more | February 2018

  7. Slide 7: Our Strategic Priorities

    Slide 7: Our Strategic Priorities

    Our Strategic Priorities 1 Deliver at least three products to market 5 key priorities to ensure the company’s success 2 Build a commercial organization over the next 5 years 3 Bring Idorsia to profitability in a sustainable manner 4 Create a pipeline with a sales potential of CHF 5 billion 5 Utilize

  8. Slide 8: More in the pipeline – Promising compounds

    Slide 8: More in the pipeline – Promising compounds

    More in the pipeline – Resistant hypertension Fabry disease Promising compounds Management Aprocitentan Lucerastat Glucosylceramide synthase inhibitor Vasospasm associated with aneurysmal Dual endothelin Status: Advancing to subarachnoid Diversified and balanced pipeline: CNS, receptor antagonist Ph

  9. Slide 9: Lucerastat in Fabry disease

    Slide 9: Lucerastat in Fabry disease

    Lucerastat in Fabry disease Lucerastat is investigational, in development and not approved or marketed in any country. 9 Idorsia - Reaching out for more | February 2018

  10. Slide 10: Fabry disease – Medical need

    Slide 10: Fabry disease – Medical need

    Fabry disease – Medical need Fabry disease is a rare X-linked genetic disorder in which patients have a deficiency or dysfunction of the enzyme alpha-galactosidase A Standard treatment approach for Fabry disease is Enzyme Replacement Therapy (ERT), which supplies recombinant GLA to the cells 10 Idor

  11. Slide 11: Lucerastat

    Slide 11: Lucerastat

    Lucerastat • Lucerastat is a small molecule iminosugar that inhibits glucosylceramide synthase and has the potential to provide substrate reduction therapy for the oral treatment of certain lysosomal storage disorders • In an exploratory clinical study in patients with Fabry disease treated with ERT

  12. Slide 12: Summary

    Slide 12: Summary

    Summary • Fabry disease is a rare genetic disorder involving deficiency or Fabry disease dysfunction of an enzyme that breaks down fatty waste products Compound: Lucerastat in body • Lucerastat oral monotherapy offers new treatment approach Mechanism of action: with potential to alleviate symptoms o

  13. Slide 13: Aprocitentan in resistant hypertension management

    Slide 13: Aprocitentan in resistant hypertension management

    Aprocitentan in resistant hypertension management. Aprocitentan is investigational, in development and not approved or marketed in any country. 13 Idorsia - Reaching out for more | February 2018

  14. Slide 14: Resistant hypertension – Medical need

    Slide 14: Resistant hypertension – Medical need

    Resistant hypertension – Medical need • Resistant hypertension is defined by uncontrolled hypertension despite three antihypertensive drug therapies from different classes at optimal doses including a diuretic • Represents a small sub-set of hypertensive population • High cardiovascular risk factor

  15. Slide 15: Aprocitentan

    Slide 15: Aprocitentan

    Aprocitentan A novel dual ETA and ETB ERA • Oral, potent, once-a-day drug for control of blood pressure • Evaluated in a dose-finding study to explore the effects of aprocitentan (ACT-132577) – at different dose levels – on the efficacy, safety and tolerability in 490 patients with essential hyperte

  16. Slide 16: Aprocitentan dose-finding study

    Slide 16: Aprocitentan dose-finding study

    Aprocitentan Dose-finding study Placebo Aprocitentan 5 mg Aprocitentan 10 mg Aprocitentan 25 mg Aprocitentan 50 mg Lisinopril 20 mg Period I Period II Period III SB Placebo Run-in DB-treatment SB Placebo WD FU Randomization DB-EOT WD-EOT EOS Week -6 -4 -1 Day 1 2 4 8 10 Visit 1 2 3 4 5 6 7 8 Phone c

  17. Slide 17: Aprocitentan efficacy results

    Slide 17: Aprocitentan efficacy results

    Aprocitentan Phase 2 efficacy results • In the per-protocol, primary population (410 patients) after 8 weeks of treatment • Mean reduction from baseline in diastolic blood pressure: − 6.3 - 12.0 mmHg in aprocitentan groups (statistically significant dose-dependent manner) − 4.9 mmHg in the placebo g

  18. Slide 18: Aprocitentan safety results

    Slide 18: Aprocitentan safety results

    Aprocitentan Phase 2 safety results Placebo group Aprocitentan group Lisinopril group Safety population / in patients 82 327 81 Discontinuation from study 6.1% 1.2% – 3.7% 3.7% treatment due to an adverse event Cases of increased liver enzymes 1 1 – above three times the upper limit of the normal ra

  19. Slide 19: Aprocitentan conclusion from the study

    Slide 19: Aprocitentan conclusion from the study

    Aprocitentan Conclusion from the study • The effect of aprocitentan observed is clinically relevant • The effect of aprocitentan covers the 24 h period • Aprocitentan was well tolerated across all four doses in this patient population • The overall frequency of adverse events was similar on aprocite

  20. Slide 20: Aprocitentan Phase 3 plans

    Slide 20: Aprocitentan Phase 3 plans

    Aprocitentan Phase 3 plans • Based on the positive dose-finding results and following feedback from health authorities, Idorsia is currently finalizing the design of a Phase 3 study • The study will evaluate the initial and long-term effect of aprocitentan on systolic and diastolic blood pressure in

  21. Slide 21: Aprocitentan collaboration with Janssen Biotech

    Slide 21: Aprocitentan collaboration with Janssen Biotech

    Aprocitentan Collaboration with Janssen Biotech, Inc. • Janssen Biotech, Inc. and Idorsia are collaborating in respect of the development and commercialization of aprocitentan and any of its derivative compounds or products • Idorsia has received a one-time milestone payment of USD 230 million • Bot

  22. Slide 22: Summary

    Slide 22: Summary

    Summary • Aprocitentan has great potential in resistant hypertension Resistant hypertension management as an oral, once daily treatment with potent, long management lasting hypertensive effects Compound: Aprocitentan • We are collaborating with Janssen Biotech to jointly develop and Mechanism of act

  23. Slide 23: ACT-541468 in insomnia

    Slide 23: ACT-541468 in insomnia

    ACT-541468 in insomnia ACT-541468 is investigational, in development and not approved or marketed in any country. 23 Idorsia - Reaching out for more | February 2018

  24. Slide 24: Insomnia – Medical need

    Slide 24: Insomnia – Medical need

    Insomnia – Medical need • Around 10% of adults report daytime impairment as result of insomnia • Insomnia is associated with an increased risk of psychiatric disorders − Depression, Anxiety, Alcohol abuse, Drug abuse • Insomnia increases the risk of accident and injury • Insomnia is a leading cause

  25. Slide 25: Insomnia – Medical need

    Slide 25: Insomnia – Medical need

    Insomnia – Medical need Most existing sleep-promoting agents do not induce natural sleep Leading to unmet patient needs • Lack of continued benefit over time • Lack of sustained effect through the night • Impacted next day performance (residual effect) 25 Idorsia - Reaching out for more | February 2

  26. Slide 26: Insomnia – Medical need

    Slide 26: Insomnia – Medical need

    Insomnia – Medical need Most existing sleep-promoting agents have significant limitations Leading to physician concerns • Insufficient acute & long-term efficacy • Abuse potential and withdrawal effect • Problematic side effects − Next day residual effect (balance, ambulation, psychomotor response,

  27. Slide 27: ACT-541468 (DORA)

    Slide 27: ACT-541468 (DORA)

    ACT-541468 (DORA) A novel dual orexin receptor antagonist Desired profile • High in vitro and in vivo potency and efficacy • Fast onset of action • Appropriate duration of action • No deterioration of next day performance • No unmanageable drug-drug interaction • No safety issue ACT-541468 is invest

  28. Slide 28: ACT-541468 rat EEG data

    Slide 28: ACT-541468 rat EEG data

    ACT-541468 (DORA) Rat EEG data: sleep efficacy / architecture ACT-541468 (mg/kg) Active wake Quiet wake non-REM sleep REM sleep Vehicle 39.9 35.9 18.0 6.2 * Active 10 35.3 35.5 21.7 7.4 phase dosing *** *** ** 30 31.1 35.1 24.0 9.8 *** *** *** 100 27.3 34.2 27.5 11.0 Rest phase 15.3 33.5 40.4 10.8 T

  29. Slide 29: ACT-541468 Phase 1 program

    Slide 29: ACT-541468 Phase 1 program

    ACT-541468 (DORA) Phase 1 program Single-ascending dose study in healthy young male adults • Doses evaluated from 5 mg to 200 mg 3-part study in male and female young adults and elderly • Multiple-ascending dose in adults • Single-ascending dose in elderly • Multiple night-time dosing in adult and e

  30. Slide 30: ACT-541468 pharmacokinetic profile

    Slide 30: ACT-541468 pharmacokinetic profile

    ACT-541468 (DORA) Ideal pharmacokinetic profile for an insomnia medication 1000 800 Dose: 25 mg for 600 5 days 400 200 ACT-541468 (ng/ml) 0 0 24 48 72 96 120 144 168 ACT-541468 is investigational, in development and not approved or marketed in any country. 30 Idorsia - Reaching out for more | Februa

  31. Slide 31: ACT-541468 pharmacodynamic profile: fast onset

    Slide 31: ACT-541468 pharmacodynamic profile: fast onset

    ACT-541468 (DORA) Pharmacodynamic profile Fast onset of action in adult & elderly Adult Healthy Volunteer – Daytime dosing Elderly Healthy Volunteer – Daytime dosing Person performing eye movement test Reduced speed of eye movements ACT-541468 is investigational, in development and not approved or m

  32. Slide 32: ACT-541468 pharmacodynamic profile: duration

    Slide 32: ACT-541468 pharmacodynamic profile: duration

    ACT-541468 (DORA) Pharmacodynamic profile Appropriate duration of action in adult & elderly Adult Healthy Volunteer – Daytime dosing Elderly Healthy Volunteer – Daytime dosing Person performing adaptive tracking test Reduced tracking performance ACT-541468 is investigational, in development and not

  33. Slide 33: ACT-541468 next-day pharmacodynamic profile

    Slide 33: ACT-541468 next-day pharmacodynamic profile

    ACT-541468 Next-day pharmacodynamic profile No sleepiness reported on next morning Healthy adult with night-time administration Karolinska Sleepiness Scale Score 9 Very sleepy 8 Sleepy, but no effort 7 keeping awake 6 Neither 5 alert nor sleepy 4 Alert, 3 normal level 2 1 Very alert ACT-541468 is in

  34. Slide 34: ACT-541468 initial safety profile

    Slide 34: ACT-541468 initial safety profile

    ACT-541468 (DORA) Initial safety profile from Phase 1 program • No SAEs, no unexpected AEs after 110 healthy adults and elderly exposed • Starting at 25 mg, transient AEs of mild to moderate intensity were observed such as: Disturbance of attention, somnolence, fatigue, headache and dizziness • No s

  35. Slide 35: ACT-541468 Phase 2 program overview

    Slide 35: ACT-541468 Phase 2 program overview

    ACT-541468 (DORA) Phase 2 program overview • Two dose-response studies to evaluate the safety and efficacy of DORA in adult and elderly patients with insomnia • Adult study with zolpidem as an active reference − Study 1: 360 adult insomnia patients − Study 2: 58 elderly insomnia patients ACT-541468

  36. Slide 36: ACT-541468 Phase 2 results in adults

    Slide 36: ACT-541468 Phase 2 results in adults

    ACT-541468 (DORA) Phase 2 results in adult patients, announced in July 2017 • Study in adults showed a significant dose dependent decrease in WASO (average decrease of wake-time after sleep onset) at Day 1 & 2 • ACT-541468 also significantly decreased LPS (latency to persistent sleep) at Day 1 & 2 i

  37. Slide 37: ACT-541468 Phase 2 results in elderly

    Slide 37: ACT-541468 Phase 2 results in elderly

    ACT-541468 (DORA) Phase 2 results in elderly patients, announced in July 2017 • Positive results of the study confirm the efficacy and safety profile of ACT- 541468 in this population • Results of this study also showed significant decrease in WASO and LPS at Day 1&2 in a dose-dependent manner ACT-5

  38. Slide 38: Summary

    Slide 38: Summary

    Summary • Idorsia has significant expertise in the discovery and development of Insomnia DORAs Compound: ACT-541468 • DORAs have the potential to promote sleep and maintain a natural sleep architecture Mechanism of action: Dual orexin • PK/PD profile of ACT-541468 suggests an optimal combination of

  39. Slide 39: Clazosentan in cerebral vasospasm post-aSAH

    Slide 39: Clazosentan in cerebral vasospasm post-aSAH

    Clazosentan in cerebral vasospasm post-aneurysmal subarachnoid hemorrhage Clazosentan is investigational, in development and not approved or marketed in any country. 39 Idorsia - Reaching out for more | February 2018

  40. Slide 40: Vasospasm post-aSAH – Medical need

    Slide 40: Vasospasm post-aSAH – Medical need

    Vasospasm post-aSAH – Medical need aSAH is a sudden, life-threatening bleeding in the space around the brain caused by the rupture of an aneurysm 40 Idorsia - Reaching out for more | February 2018

  41. Slide 41: Clazosentan

    Slide 41: Clazosentan

    Clazosentan Highly soluble ETA selective ERA • Ideal for intravenous administration • >1’500 patients treated with clazosentan providing significant experience in vasospasm post aSAH and a well documented safety profile • CONSCIOUS-2 aneurysm secured by clipping • CONSCIOUS-3 aneurysm secured by coi

  42. Slide 42: Clazosentan CONSCIOUS-3 results

    Slide 42: Clazosentan CONSCIOUS-3 results

    Clazosentan CONSCIOUS-3 results – event rate for the components of the 1o composite endpoint RRR 35% -21% 15% 29% (95% CI) (-79 to 76%) (-97 to 26%) (-28 to 44%) (-9 to 54%) -34% 44% 54% 65% (-211 to 42%) (-5 to 70%) (22 to 72%) (38 to 80%) 25 21 21 20 18 Placebo 16 Event rate (%) Clazosentan 5 mg/h

  43. Slide 43: Clazosentan Phase 3 REVERSE study

    Slide 43: Clazosentan Phase 3 REVERSE study

    Clazosentan Phase 2 REVERSE study • REVERSE: Phase 2 study to evaluate whether clazosentan has a rapid effect in reversing angiographically-confirmed cerebral vasospasm in patients with aSAH treated by endovascular coiling or surgical clipping • Results are expected to be discussed with health autho

  44. Slide 44: Summary

    Slide 44: Summary

    Summary • Developed as intravenous infusion for prevention and treatment Cerebral vasospasm of cerebral vasopasms in patients who have suffered an aSAH Compound: Clazosentan • Has potential to prevent ischemic complications of cerebral vasoconstriction and to decrease the need for invasive Mechanism

  45. Slide 45: Cenerimod in systemic lupus erythematosus

    Slide 45: Cenerimod in systemic lupus erythematosus

    Cenerimod in systemic lupus erythematosus Cenerimod is investigational, in development and not approved or marketed in any country. 45 Idorsia - Reaching out for more | February 2018

  46. Slide 46: Systemic lupus erythematosus – Medical need

    Slide 46: Systemic lupus erythematosus – Medical need

    Systemic lupus erythematosus – Medical need • Complex, systemic, autoimmune disease of unknown etiology • Characterized by tissue damage across multiple organ systems • Severe organ damage and significant mortality in subset of patients • Limited treatment options with a high need for a new approach

  47. Slide 47: Cenerimod

    Slide 47: Cenerimod

    Cenerimod A novel S1P1 receptor modulator O N • Very potent, highly selective, S1P1 receptor modulator • Prevents lymphocytes from leaving lymph nodes and reaching target tissues N O N • Induces rapid and reversible, dose-dependent blood lymphocyte count reduction • Pharmacokinetic profile suitable

  48. Slide 48: Cenerimod Phase 2 study

    Slide 48: Cenerimod Phase 2 study

    Cenerimod Phase 2 study Phase 2 randomized, double-blind, placebo-controlled, dose-response study to investigate the biological activity, safety, and tolerability of cenerimod in adult patients with systemic lupus erythematosus 67 patients were enrolled to receive either placebo or 0.5, 1, 2 or 4 mg

  49. Slide 49: Cenerimod Phase 2 study design

    Slide 49: Cenerimod Phase 2 study design

    Cenerimod Phase 2 study Randomization EOT EOS Placebo 12 pts Part A Cenerimod 0.5 mg 12 pts Cenerimod 1.0 mg 12 pts Cenerimod 2.0 mg 12 pts Visit 1 2 3 4 5 6 7 8 9 Week Day -30 Day 1 2 4 8 12 18 23 28 Screening Treatment period Follow-up Phone calls FU 30 days 12 weeks 6 weeks 10 weeks Randomization

  50. Slide 50: Cenerimod study results

    Slide 50: Cenerimod study results

    Cenerimod Study results • A dose-response relationship for cenerimod was demonstrated, based on circulating lymphocyte counts • Cenerimod was well tolerated at all dose levels • The occurrence of adverse events was similar in all five treatment groups • As a result, cenerimod is ready to move into a

  51. Slide 51: Vamorolone in Duchenne Muscular Dystrophy

    Slide 51: Vamorolone in Duchenne Muscular Dystrophy

    Vamorolone in Duchenne Muscular Dystrophy 51 Idorsia - Reaching out for more | February 2018

  52. Slide 52: Vamorolone

    Slide 52: Vamorolone

    Vamorolone • Vamorolone is a novel compound for the treatment of Duchenne Muscular Dystrophy • It holds potential to better preserve muscle function and prolong ambulation for the patient, without some of the side effects associated with glucocorticoid therapy • A Phase 2a program is currently under

  53. Slide 53: Idorsia's other clinical development assets

    Slide 53: Idorsia's other clinical development assets

    Idorsia’s other clinical development assets 53 Idorsia - Reaching out for more | February 2018

  54. Slide 54: ACT-246475 – P2Y12 receptor antagonist

    Slide 54: ACT-246475 – P2Y12 receptor antagonist

    ACT-246475 – P2Y12 receptor antagonist for acute coronary syndrome • In development for the prevention of myocardial damage in acute coronary syndrome • Targeted for individuals at risk of a myocardial infarction • Meets a very specific pharmacokinetic profile, which requires the product to be well-

  55. Slide 55: ACT-539313 – selective orexin receptor antagonist

    Slide 55: ACT-539313 – selective orexin receptor antagonist

    ACT-539313 – selective orexin 1 receptor antagonist (SORA) for anxiety disorders • In development for the potential treatment of anxiety disorders • Potent antagonist, brain-penetrating • Shown anxiolytic (anxiety inhibiting) effects after oral administration in four different preclinical models rep

  56. Slide 56: ACT-774312 – CRTH2 receptor antagonist

    Slide 56: ACT-774312 – CRTH2 receptor antagonist

    ACT-774312 – CRTH2 receptor antagonist for asthma and allergy disorders • In development for the treatment of asthma and allergy disorders for patients whose disease is not fully controlled with conventional therapies • Current evidence suggests that treatment with a CRTH2 receptor antagonist can co

  57. Slide 57: ACT-709478 – T-type calcium channel blocker

    Slide 57: ACT-709478 – T-type calcium channel blocker

    ACT-709478 – T-type calcium channel blocker for epilepsy • In development for certain forms of generalized epilepsy • ACT-7091478 is a selective, orally available triple T-type calcium channel blocker. • The compound exhibits good tolerability after single-dose administration in humans and PK proper

  58. Slide 58: More science – Bursting with ideas

    Slide 58: More science – Bursting with ideas

    More science – Bursting with ideas 58 Idorsia - Reaching out for more | February 2018

  59. Slide 59: Idorsia's drug discovery approach

    Slide 59: Idorsia's drug discovery approach

    Idorsia’s drug discovery approach Single-center approach Few platforms of expertise Fully integrated research informatics Multiple therapeutic areas Focus on High medical input small molecules 59 Idorsia - Reaching out for more | February 2018

  60. Slide 60: Our drug discovery process

    Slide 60: Our drug discovery process

    More joy – Transforming the horizon Our drug discovery process Preclinical Development Clinical Development Registration Launch Molecular-Biology Biochemistry (High Structural Biology (Target Finding) Throughput Screening) And Molecular Modeling Targets Hits Research Information Medicinal Management

  61. Slide 61: Financial information

    Slide 61: Financial information

    Financial information 61 Idorsia - Reaching out for more | February 2018

  62. Slide 62: Operating results

    Slide 62: Operating results

    Operating results -48 Non-GAAP US-GAAP 158 -75 -27 8 -10 -6 -8 Revenues Research Development G&A Non-GAAP D&A SBC US-GAAP Operating Operating results results Financial results as of Dec 31, 2017 62 Idorsia - Reaching out for more | February 2018

  63. Slide 63: Net results

    Slide 63: Net results

    Net results Non-GAAP US-GAAP 8 5 -8 -14 -3 -7 Operating results Financial Income Tax Non-Controlling Net results results results Interests Financial results as of Dec 31, 2017 63 Idorsia - Reaching out for more | February 2018

  64. Slide 64: Cash flow

    Slide 64: Cash flow

    Cash flow 14 227 -150 1'091 1'000 Cash @ OPEX J&J Capex Liquidity @ Demerger (excl. milestone) milestone & WCR Dec 31, 2017 Financial results as of Dec 31, 2017 64 Idorsia - Reaching out for more | February 2018

  65. Slide 65: Liquidity

    Slide 65: Liquidity

    Liquidity 1’091 250 218 Cash deposits long-term Cash deposits 1'000 short-term Cash and 622 Cash Equivalents Liquidity @ Liquidity @ Demerger Dec 31, 2017 Financial results as of Dec 31, 2017 65 Idorsia - Reaching out for more | February 2018

  66. Slide 66: Convertible bond

    Slide 66: Convertible bond

    Convertible bond 580 84 445 445 84 80 Equity component 496 361 365 Debt component CB @ CB post conversion of CB @ Demerger 1st tranche Dec 31, 2017 Financial results as of Dec 31, 2017 66 Idorsia - Reaching out for more | February 2018

  67. Slide 67: Potential issued shares

    Slide 67: Potential issued shares

    Potential issued shares 157.8 162.6 4.8 38.7 Equity instruments 50.5 Equity derivatives Issued common 119.1 shares 107.3 Potential shares @ Potential shares @ Demerger Dec 31, 2017 Financial results as of Dec 31, 2017 67 Idorsia - Reaching out for more | February 2018

  68. Slide 68: Financial Guidance

    Slide 68: Financial Guidance

    Financial Guidance 2018 Unforeseen events and potential milestone expenses excluded, we expect non-GAAP operating expenses for 2018 to be around 390 million Swiss francs, mainly depending on when each of the different Phase 3 programs commences 68 Idorsia - Reaching out for more | February 2018

  69. Slide 69: More experience – Driving innovation

    Slide 69: More experience – Driving innovation

    More experience – Driving innovation 69 Idorsia - Reaching out for more | February 2018

  70. Slide 70: Idorsia has a strong and visionary leadership team

    Slide 70: Idorsia has a strong and visionary leadership team

    Idorsia has a strong and visionary leadership team with the power and drive to create more remarkable innovations and more new medicines 70 Idorsia - Reaching out for more | February 2018

  71. Slide 71: Idorsia management team

    Slide 71: Idorsia management team

    Idorsia management team Jean-Paul Clozel Martine Clozel Guy Braunstein André C. Muller Chief Executive Officer Chief Scientific Officer Head of Global Clinical Development Chief Financial Officer Andrew C. Weiss Head of Investor Relations & Alex Khatuntsev Oliver Peinelt Olivier Lambert Corporate Co

  72. Slide 72: Idorsia Board of Directors

    Slide 72: Idorsia Board of Directors

    Idorsia Board of Directors Jean-Pierre Garnier Robert J. Bertolini Jean-Paul Clozel Chairman of the board of directors Member of the board of directors Chief Executive Officer John J. Greisch David Stout Herna Verhagen Member of the board of directors Member of the board of directors Member of the b

  73. Slide 73: Be prepared for more

    Slide 73: Be prepared for more

    Be prepared for more 73 Idorsia - Reaching out for more | February 2018

Source: Internet Archive copy of idorsia.com

More decks from Idorsia Ltd.

All 55 Idorsia decks